The randomized, double-blind, placebo-controlled, phase III trial BROCADE3 evaluated the efficacy of adding the PARPi Veliparib to carboplatin and paclitaxel in a population of gBRCA advanced HER2-negative BC patients [73]. The gene discussed is ERBB2; the disease is breast cancer.